nilotinib nilotinib nilotinib, sold under the brand name tasigna marketed worldwide by novartis, is a medication used to treat chronic myelogenous leukemia (cml) which has the philadelphia chromosome. it may be used both in initial cases of chronic phase cml as well as in accelerated and chronic phase cml that has not responded to imatinib. it is taken by mouth. nilotinibclinical datatrade namestasigna, othersother namesamn107ahfs/drugs.commonographmedlineplusa608002license data eu ema: by inn us dailymed: nilotinib pregnancycategory au: d routes ofadministrationby mouthatc codel01ea03 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only uk: pom (prescription only) us: ℞-only eu: rx-only pharmacokinetic databioavailability30%protein binding98%metabolismliver (mostly cyp3a4-mediated)elimination half-life15-17 hoursexcretionfaeces (93%)identifiers iupac name 4-methyl-n--3- benzamide cas number641571-10-0 n (base)pubchem cid644241iuphar/bps5697drugbankdb04868 ychemspider559260 yuniif41401512xkeggd08953 ychebichebi:52172 ychemblchembl255863 ypdb ligandnil (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid5042663 echa infocard100.166.395 chemical and physical dataformulac28h22f3n7omolar mass529.527 g·mol−13d model (jsmol)interactive image smiles cc1ccc(cc1nc2nccc(n2)c3cccnc3)c(=o)nc4cc(cc(c4)n5cc(nc5)c)c(f)(f)f inchi inchi=1s/c28h22f3n7o/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16h,1-2h3,(h,35,39)(h,33,36,37) ykey:hhziurlswuihrb-uhfffaoysa-n y ny (what is this?) (verify) common side effects may include low platelets, low white blood cells, anemia, rashes, vomiting, diarrhea, and joint pains. other serious side effects may include qt prolongation, sudden death, pancreatitis, and liver problems. it is not safe for use during pregnancy. nilotinib is a bcr-abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell. nilotinib was approved for medical use in the united states in 2007. it is on the world health organization's list of essential medicines. medical uses nilotinib is used to treat philadelphia chromosome (ph+)-positive chronic myelogenous leukaemia. adverse effects